Literature DB >> 23911075

Suppression of MOG- and PLP-induced experimental autoimmune encephalomyelitis using a novel multivalent bifunctional peptide inhibitor.

Ahmed H Badawi1, Teruna J Siahaan.   

Abstract

Previously, bifunctional peptide inhibitors (BPI) with a single antigenic peptide have been shown to suppress experimental autoimmune encephalomyelitis (EAE) in an antigen-specific manner. In this study, a multivalent BPI (MVBMOG/PLP) with two antigenic peptides derived from myelin oligodendrocyte glycoprotein (MOG38-50) and myelin proteolipid protein (PLP139-151) was evaluated in suppressing MOG38-50- and PLP139-151-induced EAE. MVBMOG/PLP significantly suppressed both models of EAE even when there was some evidence of epitope spreading in the MOG38-50-induced EAE model. In addition, MVBMOG/PLP was found to be more effective than PLP-BPI and MOG-BPI in suppressing MOG38-50-induced EAE. Thus, the development of MVB molecules with broader antigenic targets can lead to suppression of epitope spreading in EAE.
© 2013.

Entities:  

Keywords:  Antigen-presenting cell; BPI; Bifunctional peptide inhibitor; EAE; Epitope spreading; Experimental autoimmune encephalomyelitis; MOG; MVB; PLP; T cell; bifunctional peptide inhibitor; experimental autoimmune encephalomyelitis; multivalent BPI; myelin oligodendrocyte glycoprotein; proteolipid protein

Mesh:

Substances:

Year:  2013        PMID: 23911075      PMCID: PMC4139121          DOI: 10.1016/j.jneuroim.2013.07.009

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  36 in total

1.  Mechanisms of action of glatiramer acetate in multiple sclerosis.

Authors:  O Neuhaus; C Farina; H Wekerle; R Hohlfeld
Journal:  Neurology       Date:  2001-03-27       Impact factor: 9.910

Review 2.  Formation and function of the immunological synapse.

Authors:  P Anton van der Merwe
Journal:  Curr Opin Immunol       Date:  2002-06       Impact factor: 7.486

Review 3.  T-cell activation: a multidimensional signaling network.

Authors:  Su-Yi Tseng; Michael L Dustin
Journal:  Curr Opin Cell Biol       Date:  2002-10       Impact factor: 8.382

4.  Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence.

Authors:  N Goebels; H Hofstetter; S Schmidt; C Brunner; H Wekerle; R Hohlfeld
Journal:  Brain       Date:  2000-03       Impact factor: 13.501

5.  Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders.

Authors:  Paolo A Muraro; Klaus-Peter Wandinger; Bibiana Bielekova; Bruno Gran; Adriana Marques; Ursula Utz; Henry F McFarland; Steve Jacobson; Roland Martin
Journal:  Brain       Date:  2003-01       Impact factor: 13.501

Review 6.  Classification of demyelinating diseases at the interface between etiology and pathogenesis.

Authors:  H Lassmann
Journal:  Curr Opin Neurol       Date:  2001-06       Impact factor: 5.710

7.  The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Authors:  Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Journal:  Nature       Date:  2002-11-07       Impact factor: 49.962

Review 8.  Epitope spreading: a mechanism for progression of autoimmune disease.

Authors:  V K Tuohy; R P Kinkel
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2000       Impact factor: 4.291

9.  T cell receptor signaling precedes immunological synapse formation.

Authors:  Kyeong-Hee Lee; Amy D Holdorf; Michael L Dustin; Andrew C Chan; Paul M Allen; Andrey S Shaw
Journal:  Science       Date:  2002-02-22       Impact factor: 47.728

10.  Controlling immune response and demyelination using highly potent bifunctional peptide inhibitors in the suppression of experimental autoimmune encephalomyelitis.

Authors:  P Kiptoo; B Büyüktimkin; A H Badawi; J Stewart; R Ridwan; T J Siahaan
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

View more
  9 in total

1.  Multivalent Soluble Antigen Arrays Exhibit High Avidity Binding and Modulation of B Cell Receptor-Mediated Signaling to Drive Efficacy against Experimental Autoimmune Encephalomyelitis.

Authors:  Brittany L Hartwell; Chad J Pickens; Martin Leon; Cory Berkland
Journal:  Biomacromolecules       Date:  2017-05-17       Impact factor: 6.988

Review 2.  Peptides and peptidomimetics as immunomodulators.

Authors:  Ameya S Gokhale; Seetharama Satyanarayanajois
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

3.  Routes of administration and dose optimization of soluble antigen arrays in mice with experimental autoimmune encephalomyelitis.

Authors:  Sharadvi Thati; Christopher Kuehl; Brittany Hartwell; Joshua Sestak; Teruna Siahaan; M Laird Forrest; Cory Berkland
Journal:  J Pharm Sci       Date:  2014-12-01       Impact factor: 3.534

4.  Synthesis of a Bifunctional Peptide Inhibitor-IgG1 Fc Fusion That Suppresses Experimental Autoimmune Encephalomyelitis.

Authors:  Derek R White; Zahra Khedri; Paul Kiptoo; Teruna J Siahaan; Thomas J Tolbert
Journal:  Bioconjug Chem       Date:  2017-06-22       Impact factor: 4.774

Review 5.  Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases.

Authors:  Mario E G Moral; Teruna J Siahaan
Journal:  Curr Top Med Chem       Date:  2017       Impact factor: 3.295

6.  Bifunctional Peptide Inhibitors Suppress Interleukin-6 Proliferation and Ameliorates Murine Collagen-Induced Arthritis.

Authors:  Barlas Büyüktimkin; Paul Kiptoo; Teruna J Siahaan
Journal:  J Clin Cell Immunol       Date:  2014-12

7.  Immune Tolerance Induction against Experimental Autoimmune Encephalomyelitis (EAE) Using A New PLP-B7AP Conjugate that Simultaneously Targets B7/CD28 Costimulatory Signal and TCR/MHC-II Signal.

Authors:  Ahmed H Badawi; Paul Kiptoo; Teruna J Siahaan
Journal:  J Mult Scler (Foster City)       Date:  2015-12

8.  In Silico Perspectives on the Prediction of the PLP's Epitopes involved in Multiple Sclerosis.

Authors:  Zahra Zamanzadeh; Mitra Ataei; Seyed Massood Nabavi; Ghasem Ahangari; Mehdi Sadeghi; Mohammad Hosein Sanati
Journal:  Iran J Biotechnol       Date:  2017-03       Impact factor: 1.671

Review 9.  Antigen-Specific Treatment Modalities in MS: The Past, the Present, and the Future.

Authors:  Judith Derdelinckx; Patrick Cras; Zwi N Berneman; Nathalie Cools
Journal:  Front Immunol       Date:  2021-02-19       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.